BCR-ABL Hits at Mitosis; Implications for Chromosomal Instability, Aneuploidy and Therapeutic Strategy by Katarzyna Piwocka et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1 
BCR-ABL Hits at Mitosis; Implications for 
Chromosomal Instability, Aneuploidy  
and Therapeutic Strategy 
Katarzyna Piwocka, Kamila Wolanin,  
Monika Kusio-Kobialka and Paulina Podszywalow-Bartnicka  
Nencki Institute of Experimental Biology, Polish Academy of Sciences 
Poland 
1. Introduction 
1.1 Genomic and chromosomal instability in CML 
An unstable genome is a common hallmark of nearly all solid tumors and most of leukemias 
in contrast to normal, healthy cells which are able to maintein genome integrity (Negrini et 
al., 2010). Genomic instability could result from changes in chromosome structure and 
number as well as changes on the DNA level. Chromosomal instability (CIN) arises from 
unproper chromosome segregation as well as division defects and leads to aneuploidy 
(Foijer, 2010), whereas accumulation of mutations and DNA alterations usually is an effect 
of the defective repair systems and DNA damage response in cancer cells (Economopoulou 
et al., 2011).  
Chronic myeloid leukemia (CML) cells expressing the BCR-ABL tyrosine kinase have been 
found to accumulate mutations as well as chromosomal abnormalities. One of the first 
indications that CML correlates with additional chromosome changes has been presented in 
1987 (Alimena et al., 1987). Moreover, authors showed that the rate of chromosomal 
anomalies increased during the blastic transformation. In the next years this has been also 
confirmed by other authors (Hagemeijer, 1987; Johansson et al., 2002; Su et al., 1999; 
Suzukawa et al., 1997). Later, random aneuploidy rate between chromosomes 9 and 18 has 
been reported in CML patients – both, untreated as well as upon imatinib therapy (Amiel et 
al., 2006). In broader analysis of CML patients it was found that chromosomal instability 
caused by centrosomal aberrations significantly correlated with the disease progression 
(Giehl et al., 2005). In the chronic phase only one sample out of 18 showed additional 
karyotypic alterations, in contrast to blast crisis where 73% patients (11/16) displayed 
additional karyotype alterations. The observation that CML patients have karyotype 
aberrations was confirmed in other studies where complex chromosomal rearrangements 
(CCR) were investigated (Babicka et al., 2006). By using cytogenetics, the FISH, and 
multicolor FISH (mFISH) methods, a very high level of the genomic instability at the 
chromosomal level, in cells obtained from chronic myeloid leukemia patients was observed.  
Altogether, it was shown that the aberrations associated with the progression of BCR-ABL-
positive CML chronic phase to the aggressive blast crisis include additional chromosomes 
(Ph1, +8, +19), isochromosome 17q (associated with the loss of p53), reciprocal 
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translocations, loss-of-heterozygosity at 14q32, homozygous mutations/deletions of pRb 
and p16/ARF, and mutations in p53 and RAS (Calabretta & Perrotti, 2004). The possible 
mechanisms participating in the BCR-ABL-mediated aneuploidy will be broadly described 
and discussed in the next paragraphs. 
BCR-ABL has been also indicated as a promoter of secondary DNA mutations in CML 
(Burke & Carroll, 2010). This is the effect of the defective DNA damage response and DNA 
repair mechanisms found in CML cells. DNA damage can occur as single-nucleotide 
alterations, single-strand breaks (SSB), or double-strand breaks (DSB). Double-strand breaks 
are proposed to be the most mutagenic, as neither strand remains intact to serve as a 
template for repair. Single-nucleotide alterations are repaired by mismatch repair (MMR) or 
nucleotide excision repair (NER) mechanisms. Single or double-strand breaks are repaired 
by either high-fidelity homologous recombination repair (HRR) or non-homologous end-
joining (NHEJ), when a sister chromatid is not available as a template. The last mechanism is 
error-prone and can lead to short deletions in the repaired strands.  
Data from different laboratories collectively indicate that BCR-ABL promotes dysfunctions 
of nearly all mechanisms participating in the DNA repair. It is known that BCR-ABL cells 
treated with genotoxic agents present higher levels of DNA damage and aberrant repair 
systems, leading to the accumulation of DNA errors (Brady, 2003; Laurent et al., 2003; 
Slupianek et al., 2002). Studies from Skorski’s group clearly showed that expression of BCR-
ABL affects different mechanisms participating in the DNA repair. They found that BCR-
ABL modifies the repair of DNA double-strand breaks (Koptyra et al., 2008; Nowicki et al., 
2004; Slupianek et al., 2006). Briefly, CML cells produced increased rate of DSBs in S and 
G2/M phases of the cell cycle, as a result of oxidative DNA damage caused by BCR-ABL. 
These breaks were repaired, however with a high mutation rate and large deletions, as a 
result of defective HRR and NHEJ repair systems, respectively. Moreover, they found that 
BCR-ABL is able to inhibit both, mismatch repair (MMR) and inhibit apoptosis as well as to 
induce point mutations (Stoklosa et al., 2008). Upon this, CML cells were able to survive 
treatment leading to generation of the O(6)-methylguanine and O(4)-methylthymine 
recognized by the MMR system, however they displayed 15-fold higher mutation frequency 
than parental counterparts.  
Deutsch et al indicated that DNA-PKcs, a protein involved in the NHEJ repair system, may 
be downregulated by BCR-ABL (Deutsch et al., 2001). This decrease was proteasome- and 
tyrosine kinase-dependent, as it was reversed by proteasome as well as tyrosime kinase 
inhibitors. Alternatively, the role of DNA-PKcs has been recently indicated to switch on the 
backup-NHEJ system, which is more error-prone (Poplawski & Blasiak, 2010). It was also 
shown that BCR-ABL upregulates the error-prone DSB repair pathways, particularly single-
strand annealing and non-homologous end-joining due to an increased level of DNA-end-
processing factor CtIP (Salles et al., 2011). Additionally, BCR-ABL also promotes the DNA 
DSB repair by using the highly mutagenic single-strand annealing (SSA) pathway which 
involves single repeats (Fernandes et al., 2009). This required the active Ras and PI3K 
pathways, acting downstream of the Y177 site of BCR-ABL, which is a major regulatory site 
for ROS induction and is necessary for the optimal activation of the PI3K and Ras pathways. 
Moreover, using stromal cell lines authors also showed that the stromal cell-conditioned 
media increased the SSA frequency, measured in K562 cells in the presence or absence of 
imatinib. This supported the hypothesis that microenvironment additionaly promotes 
mutagenesis in CML cells. 
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Altogether, there is no doubt, that defects in DNA repair mechanisms and genomic 
surveillance in CML cells are an effect of the expression of BCR-ABL itself. However, there 
was still an open question, whether occurrence of the genomic instability participates in the 
development of the blast crisis phase (Penserga & Skorski, 2007; Shet et al., 2002). This has 
been strongly indicated to play a significant role in the malignant progression of the disease 
by many authors (Burke & Carroll, 2010; Salleset al., 2011; Skorski, 2008; Skorski, 2011).  
Till now, convincing data was presented and it seems clear, that genetic instability, 
accumulation of mutations and additional chromosomal alterations are the major factors 
involved in the CML progression and resistance to cell death. This leads to an accumulation 
of additional genetic aberrations and changes in gene expression, which result in the 
expansion of differentiation-arrested and increasingly malignant cell clones. Importantly, 
genetic instability of tyrosine kinase refractory cells, including leukemia stem cells (LSCs) 
has also recently been proposed as a reason for their fast transformation leading to the 
generation of additional resistant clones and transformation to a blast phase (Skorski, 2011). 
This mechanism could be responsible for clonal evolution and expansion causing finally 
relapse and malignant progression.  
The current model of blastic transformation proposed recently by Perotti (Perrotti et al., 
2010), indicates that acquiring of additional genetic and epigenetic changes by LSCs or their 
progeny causes leukemia transformation from the chronic phase to the advanced phases. 
This can explain the complexity of the disease progression and blast crisis as well as the 
inability to find common features of cells in blast crisis and specific secondary genetic 
aberrations. Most likely different mutations and aberrations are cumulated to obtain the 
critical point allowing the disease to progress. Thus, it will be very difficult to plan the 
therapeutic strategy against genetically unstable LSCs, resistant to tyrosine kinase inhibitors, 
with the already used agents and probably novel therapies need to be developed. 
2. The role of aberrant divisions in CML cells 
It has been known for more than a century that neoplastic cells could exhibit disturbances of 
the cell division process (Boveri, 1902, 1914). Boveri observed that sea urchin embryos 
manipulated to undergo mitosis in the presence of multipolar spindles produced aneuploid 
progeny and proposed that tumors arise from normal cells becoming aneuploid as a result 
of aberrant mitoses. Boveri’s theory that division errors and aneuploidy could lead to cancer 
development has been revisited during the last decade (Duesberg et al., 2006; Holland & 
Cleveland, 2009; Weaver & Cleveland, 2006).  
Today, it is commonly accepted that aberrant mitoses result in chromosomal instability 
(CIN), leading to the gain or loss of whole or large fragments of chromosomes, which are the 
main form of genomic instability in cancers. As it was mentioned in the previous chapter, it 
is fully convincing that expression of BCR-ABL leads to significant chromosomal 
aberrations. Moreover, these abnormalities increase along with the disease progression, 
participating in the blastic transformation. Below, we present current data concerning the 
role of BCR-ABL-mediated defects in the mechanisms controlling cell division as well as the 
role of BRCA1 in the development of aneuploidy in CML. 
2.1 Centrosomal multiplication 
Centrosomes are small organelles with a crucial role in the formation of bipolar mitotic 
spindle, which is necessary for the accurate segregation of chromosomes (Fukasawa, 2007; 
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Rusan & Rogers, 2009; Tanenbaum & Medema, 2010). Briefly, they are formed by paired 
centrioles surrounded by a protein matrix of pericentriolar material, including pericentrin. 
Their function is to nucleate and anchor microtubules to form an interphase cytoplasmic-
microtubule network and mitotic spindle. During the cell division, each daughter cell 
receives one centrosome, thus the centrosome has to duplicate before the next mitosis. This 
takes place during the S phase and is driven at least partially by the Cdk2-cyclin E complex. 
Coordination of the DNA and centrosome replication is crucial to avoid their 
overduplication. Two mature centrosomes are generated at the late G2 phase and they 
become the spindle poles. It was shown that the DNA damage checkpoint proteins, such as 
ATM, ATR, Chk1 and Chk2 and others also localize at the centrosomes (Zhang et al., 2007). 
It seems that these proteins interact with gamma-tubulin and are involved in the controlling 
of microtubule kinetics during the DNA damage response. It was reported that DNA 
damage leads to centrosome amplification in the G2 phase as a result of cell cycle arrest 
(Inanc et al., 2010). Studies performed by Dodson and colleagues showed the involvement of 
ATM in the centrosome amplification in response to DNA damage, however gene targeting 
of ATM reduced, but did not abrogate completely centrosome amplification (Dodson et al., 
2004). Alternatively, data from lymphoid gamma-irradiated cells showed that neither ATM 
nor ATR kinases are involved in this process, however Chk1-dependent signaling seems to 
be crucial  (Bourke et al., 2007). This issue still needs to be clarified. 
It is commonly accepted that the appearance of supernumerary centrosomes is associated 
with aberrant mitoses and chromosomal instability. Multipolar mitoses, lagging 
chromosomes or multinuclei are observed in cells with overduplicated centrosomes. Cells 
with three centrosomes usually undergo cytokinesis and some of the generated cells are 
viable, however aneuploid. Cells with multipolar (>3) spindles fail to undergo cytokinesis 
and can become polyploid if they are p53-deficient and are able to continue the cell cycle 
(Godinho et al., 2009).  
Centrosome abnormalities are commonly observed in cancers and participate in the 
chromosomal instability and tumorigenesis (Carroll et al., 1999; Duensing & Duensing, 2010; 
Pihan et al., 2001). As mentioned before, mutlipolar mitosis as a result of centrosome 
overduplication can lead to gross chromosome missegregation and cell death. Thus cancer 
cells with supernumerary centrosomes possess the ability to suppress multipolar mitoses 
due to the inactivation, clustering or asymmetric segregation of extra centrosomes (Brinkley, 
2001; Godinhoet al., 2009). This results in the formation of a bipolar, functional, however not 
symmetric mitotic spindle and so called mitotic stability of aneuploid cancer cells. 
Abnormalities in the number of centrosomes were also found in leukemias. It was reported 
that defects in the number of centrosomes caused by the p53 mutation and cyclin E 
overexpression, detected in bladder cancers, led to centrosome amplification and 
chromosomal instability (Kawamura et al., 2004). Moreover, the centrosome aberrations 
were proposed as one of the main factors responsible for aneuploidy in acute myeloid 
leukemia (Kramer et al., 2003; Neben et al., 2003). Studies of CD34+ Ph+ cells isolated from 
chronic myeloid leukemia patients showed that centrosome aberrations correlate with the 
stage of the disease and aneuploidy (Giehl et al., 2005). In these studies freshly isolated cells 
from CML patients, in the chronic phase or blast crisis, were stained for pericentrin and 
gamma-tubulin to analyse the number as well as the structure of centrosomes. Moreover, 
they were studied for additional karyotypic abnormalities. Importantly, a strong correlation 
between the increase of centrosome aberrations, CML progression and blastic 
transformation was found. As centrosome defects were indicated as en early detectable 
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feature of CML, they have been proposed as a cause of karyotype instability and aneuploidy 
in CML progenitor cells as well as a valuable prognostic factor. In the long-term in vitro 
studies, using a cellular model of the chronic phase of CML, authors confirmed, that 
expression of BCR-ABL leads to significant centrosomal hypertrophy visible already after 4 
weeks of BCR-ABL expression (Giehl et al., 2007). This increased upon the next 10 weeks of 
propagation and correlated with the clonal expantion of aneuploid cells. 
We also found, using a mouse cellular model of CML, that the stable expression of low or 
high level of BCR-ABL in mouse progenitor 32D cells leads to the generation of cells with 
supernumerary centrosomes (Wolanin et al., 2010). This was accompanied by increased 
percentage of cells with aberrant mitoses, particularly multipolar spindles, lagging 
chromosomes and multinuclei. The presence of aberrant cells correlated with the level of 
BCR-ABL expression, indicating that the BCR-ABL itself is responsible for these 
abnormalities. Interestingly, Patel and colleagues presented that CML cells have defects in 
the centrosome-centriole cycle (Patel & Gordon, 2009). They showed that p210 (BCR-ABL1) 
and p145 (ABL1) are both, centrosome-associated proteins and form a complex with the 
pericentriolar protein, pericentrin. Numerical and structural centrosomal abnormalities 
were found in CML cell lines and in primary CD34+ cells from CML patients as a result of 
an increased level of separase participating in the abnormalities in the centrosome-centriole 
cycle. They also confirmed the previous data that abnormal centrosome distribution, 
amplification and loss are more evident in the advanced stages of CML. 
Although the tyrosine kinase inhibitors are very potent, selective and successful therapeutic 
agents for treatment of leukemia as well as some solid tumors it can not be neglected that 
some reports indicated that they can lead to centrosome aberrations in cancer as well as 
normal cells (Fabarius et al., 2005; Fabarius et al., 2008; Giehl et al., 2010). This was caused 
by blocking cells in the G1/S transition and the inhibition of cell growth which was 
followed by centrosomal aberrations. This should be taken into consideration with regards 
to the potential side-effects as well as a possible reason of dangerous clonal chromosomal 
abnormalities observed in BCR-ABL-negative progenitor cells under imatinib therapy. 
2.2 Mitotic checkpoint failure 
The spindle assembly checkpoint (SAC) plays a major role in the division control and 
segregation of sister chromatids, preventing occurence of aneuploidy (Chin & Yeong, 2010; 
Kops, 2008; Logarinho & Bousbaa, 2008; Nezi & Musacchio, 2009). SAC proteins, including 
Mad1 (mitotic arrest-deficient protein 1), Mad2, Bub1 (budding uninhibited by 
benzimidazoles 1), BubR1 (Bub1-related kinase 1) and Bub3 are recruited to unattached or 
tensionless kinetochores, forming mitotic checkpoint complex, which inhibits the anaphase 
promoting complex (APC). This protects cells from preearly anaphase entry and unproper 
segregation of chromatids. In physiological conditions the mitotic checkpoint is temporarily 
activated until the mitotic spindle is properly formed, whereas in anticancer therapy it is 
activated upon treatment with a group of microtubule damaging agents, such as taxanes 
and vinca alcaloids. Both interfere with tubulin organization and spindle formation, leading 
to the cell cycle arrest in mitosis and eventually cell death.  
It is known that the complete loss of the mitotic checkpoint function results in embryonic 
lethality, what was shown in Caenorhabditis  elegans (Kitagawa & Rose, 1999) as well as in 
mammalian cells (Michel et al., 2001; Schliekelman et al., 2009). Alternatively, partial loss of 
its function leads to chromosomes missegregation and chromosomal instability (Bharadwaj 
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& Yu, 2004; Ito & Matsumoto, 2010). This was due to the inability to activate the mitotic 
checkpoint and to arrest in mitosis in response to some disturbances. Instead - further 
progression of mitosis eventually leads to aberrant divisions and unproper chromosomes 
segregation. 
Dysfunctions of the mitotic checkpoint were reported in different types of cancers (Baker et 
al., 2005; Bannon & Mc Gee, 2009; Tanaka & Hirota, 2009). They correlated with aneuploidy, 
disease progression and the increase of aggressiveness. Interestingly, similar effects were 
observed in case of the upregulation or decreased expression of mitotic checkpoint 
members. For example, the Mad2 protein has been recently proposed as a critical factor 
leading to aneuploidy in cancers with defects in the Rb and p53 pathways (Schvartzman et 
al., 2011). Authors found that Mad2 expression is repressed by p53 via the Rb pathway, thus 
the cancer cells lacking the Rb protein require Mad2 upregulation leading to chromosomal 
instability and tumor progression in vivo. On the other hand, also Mad2 haplo-insufficiency 
caused chromosomal instability in human cancer cells and murine primary embryonic 
fibroblasts (Michelet al., 2001).  
BubR1 dysfunctions has also been found as a cause of cancer-susceptible disorder mosaic 
variegated aneuploidy (MVA) (Suijkerbuijk et al., 2010). Similarly to Mad2, BubR1 can be 
also overexpressed in cancer, what was shown in hepatocellular carcinoma (HCC) (Liu et 
al., 2009). Authors suggest that BubR1 overexpression, which was found in 45% of patients 
correlated with later stages and was associated with worse prognosis, thus it can be used as 
a potential prognostic factor  for HCC. 
 There were indications that CML cells could have a dysfunctional mitotic checkpoint, as 
their resistance to spindle poisons was reported previously. In the K562 and Lama-84 CML 
cell lines, microtubule disruption caused either by paclitaxel, nocodazole or novel 
microtubule-targeting agent PBOX-6 led to polyploidization without the presence of 
significant apoptosis (Greene et al., 2007). Imatinib treatment minimized the formation of 
polyploid cells and enhanced the apoptotic index upon treatment of CML cells with spindle 
poisons. Resistance to paclitaxel was also shown in K562 cells (Blagosklonny, 2001), but 
mitotic checkpoint competence was not investigated. All these data suggested that BCR-
ABL could somehow affect the response to microtubule disruption; however this issue was 
not discussed by the authors. 
We have shown for the first time that the expression of BCR-ABL in mouse 32D cells 
decreases the expression of SAC proteins, such as Mad2, Bub1, Bub3 and BubR1, as well as 
their mRNA levels, what was estimated by real time RT-PCR (Wolanin et al., 2010). 
Decreased levels of the mitotic checkpoint proteins were associated with dysfunctions in the 
mitotic checkpoint competence observed upon nocodazole and paclitaxel treatment as well 
as resistance to cell death induced by these agents. We found that the inhibition of the BCR-
ABL kinase activity by imatinib reversed the observed phenotype confirming the crucial role 
of BCR-ABL.  
2.3 Aberrant expression of mitotic kinases  
Mitotic kinases have also been implicated in the regulation of the centrosome cycle, spindle 
checkpoint and microtubule-kinetochore attachment, as well as spindle assembly and 
chromosome condensation. The family of Aurora kinases consists of the following proteins: 
Aurora A, B and C. The whole family has serine/threonine kinase activity which modifies 
microtubules during chromosome movement and segregation. Aurora kinases have been 
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found at the centrosomes of interphase cells, at the poles of the bipolar spindle and in the 
midbody of the mitotic apparatus. All three Aurora kinases members are overexpressed in 
many human cancers. This correlated with chromosomal instability and clinically aggressive 
forms of disease (Fu et al., 2007; Meraldi et al., 2004). Aurora A is localized in centrosomes 
and is important for maturation, spindle assembly and metaphase I spindle orientation. It 
has two independent functions in centrosome maturation and asymmetric protein 
localization during mitosis. Ectopic overexpression of Aurora A was shown to induce 
oncogenic transformation (Katayama et al., 2003). Moreover, overexpression of Aurora A 
and aneuploidy have been proposed as predictors of poor outcome in serous ovarian 
carcinoma (Lassus et al., 2011). Also a high level of Aurora B has been reported to promote 
tetraploidy and tumorigenesis in the mouse Xenograft model (Nguyen et al., 2009). 
High expression of Aurora A in leukemia cell lines and freshly isolated leukemia CML cells 
has been presented by Ochi T et al (Ochi et al., 2009). We also showed that the expression of 
BCR-ABL leads to the mislocalization of Aurora A in the chromosomal passenger complex 
(Wolanin et al., 2006). The importance of Aurora A-dependent signaling in CML has been 
shown in studies indicating that Aurora inhibitors seem to be very effective therapeutics for 
CML treatment (Gontarewicz et al., 2008),  what will be discussed by us later. 
Another family of tubulin-associated serine/threonine kinases, Polo-like, has also received 
significant attention regarding its participation in tumorigenesis. As far, in mammalian cells 
four members of this family have been identified (PLK1-4), and each one of them has a 
distinct function. PLK1 is essentially involved in the control of mitotic steps, PLK2 and PLK3 
have been described as potential regulators of the G1 and early S phases of the cell cycle, 
PLK4 as a major centrosome duplication regulator. Polo-like kinase 1 (PLK1) is a key 
regulator of mitosis and participates in regulating this process from its entry to cytokinesis 
(Yuan et al., 2011). Transcription and translation of PLK1 is highly coordinated with cell 
cycle progression. Plk1 mRNA and protein levels begin to accumulate in the S-phase and 
reach a peak at the G2/M transition and then decline upon mitotic exit (Lee et al., 1995). At 
the G2/M phase, PLK1 regulates the Cdk1/Cyclin B1 complex promoting mitotic entry and 
regulating mitotic progression due to regulation of phosphorylation of Cyclin B1, Cdk1, 
Myt1 and Cdc25C. PLK1 also plays a role in centrosome maturation by promoting increased 
recruitment of microtubules to the spindle pole bodies. It also regulates the localization of 
Aurora A to the centrosomes for proper maturation. It is known today that all mitotic 
kinases interplay with each other and form an extensive functional network, thus targeting 
any of them has tremendous consequences for cell physiology (Lens et al., 2010). 
Additionally, it was shown that PLK1 catalysis survivin priming phosphorylation at Ser20, 
what is necessary for survivin-mediated Aurora B docking to the centromere and activation 
(Chu et al., 2010). Expression of the non-phosphorylable survivin mutant prevented Aurora 
B activation and corrected spindle microtubule attachment. We also observed that silencing 
of survivin in CML cells significantly affected CPC function and mitosis as well as proper 
completion of cytokinesis leading to the formation of giant polyploid cells (Wolanin et al., 
2006). PLK1 also regulates the spindle assembly checkpoint (Nezi & Musacchio, 2009) 
probably by phosphorylation of BubR1 and finally, regulates chromosome segregation, 
cytokinesis and mitotic exit. 
PLK1, similarly to other mitotic kinases has been shown to be upregulated in cancers, 
including lymphomas. Studies of a big group of non-Hodgkin’s lymphoma (NHLs) patients 
presented that the level of PLK1 expression was significantly lower in low-grade NHLs than 
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in high-grade and intermediate-grade NHLs. Moreover, PLK1 has been proposed as a 
valuable marker of proliferating cells, even better than the commonly used Ki67 (Mito et al., 
2005). It was also described that PLK1 is overexpressed in AML cell lines as well as in 
primary cells and its inhibition preferentially targeted lymphoid cells, indicating an 
important role of the PLK1-mediated signaling (Renner et al., 2009). Importantly, healthy 
hematopoietic progenitor CD34+ cells were much less sensitive to growth inhibition caused 
by PLK1 targeting, indicating a high potential of this therapeutic strategy. This observation 
was confirmed by studies performed by Ikezoe and colleagues, who also found PLK1 
overexpressed in a number of human leukemia cell lines and freshly isolated leukemia cells 
from individuals with acute myelogenous leukemia as well as acute lymphoblastic 
leukemia, in comparison with normal bone marrow mononuclear cells (Ikezoe et al., 2009). 
As previously, they indicated PLK1 inhibition as a potent way to inhibit proliferation and 
induce cell death in leukemia cells. Moreover, the functional link between PLK1 and mTOR 
pathway has been shown in AML cells (Renner et al., 2010). Abnormal growth of cells 
overexpressing the active form of PLK1 was reversed by rapamycin, a specific inhibitor of 
the TORC1 complex. This showed a novel aspect of PLK1’s role in leukemia and opened 
new therapeutic possibilities.  
In chronic myeloid leukemia, PLK1was found to be expressed in the phosphorylated form 
in the CML cell line K562 as well as in primary CML cells from patients (Gleixner et al., 
2010). Studies presenting the potential of the PLK1 inhibitors in therapy against CML were 
performed and indicate an important role of PLK1 in CML development and progression. 
They will be discussed in a detailed way in the chapter dedicated to anti-mitotic therapies 
against leukemia. 
3. BCR-ABL-mediated downregulation of BRCA1 
BRCA1, a tumor suppressor isolated in 1994 (Miki et al., 1994) has been implicated in a 
broad range of cellular processes, including DNA repair, cell cycle checkpoint control, cell 
division and gene transcription (Linger & Kruk, 2010; Thompson, 2010; Wu et al., 2010; Yang 
& Xia, 2010). It is a known familiar ovarian and breast cancer-specific tumor suppressor, 
however today it seems that it is involved in the development of other types of cancers as 
well. The protein contains two motifs: a RING domain at the N-terminus and two tandem 
copies of BRCT domain at the C-terminus (Baer, 2001). In vivo it exists in a heterodimeric 
complex with the BRCA1-associated RING domain (BARD1) protein, which resembles 
BRCA1 (Wu et al., 1996).  
The first observation that BRCA1 protein is nearly undetectable in leukemia cells from 
chronic myeloid leukemia (CML) patients has been made by Deutsch et al (Deutsch et al., 
2003). They found a significant downregulation of BRCA1 in primary CD34+ cells obtained 
from both, the chronic phase and the blast crisis patients as well as in cell lines expressing 
BCR-ABL. This was not accompanied by a decrease of the  BRCA1 mRNA, what was studied 
by real-time RT-PCR in one of the investigated cell lines.  
Our group studied the direct influence of BCR-ABL on the BRCA1 expression, using the 
previously mentioned mouse progenitor 32D cell line stably expressing with BCR-ABL, 
particularly in clones, expressing low and high BCR-ABL levels (Fig.1A), (Wolanin et al., 
2010). We found that BCR-ABL expression leads to a strong decrease of BRCA1 at the 
protein level. This was reversed by treatment with imatinib, a specific inhibitor of the BCR-
ABL tyrosine kinase, confirming dependence on the tyrosine kinase activity (Fig. 1B). The 
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lack of a significant decrease of mRNA confirmed the previous observation that BCR-ABL 
affects the posttranscriptional stages of protein expression. Incubation with the proteasome 
inhibitor MG132 did not lead to an increase at the BRCA1 protein level (Fig. 1C), thus 
excluding the possibility that increased degradation is responsible for the protein 
downregulation.  
Recently, it was shown that BCR-ABL interferes with the Fanconi Anemia/BRCA1 pathway, 
thus increasing the predisposition to DNA repair errors and development of centrosomal 
and chromosomal aberrations (Valeri et al., 2010). The interference of BCR-ABL with the 
formation of BRCA1 and FANCD2 nuclear foci was observed in hematopoietic progenitors 
from CML patients. These authors also showed that the ectopic expression of BRCA1 
reverted the generation of aberrant centrosomes induced by BCR-ABL. This suggests, 
however not directly studied, that overexpression of BRCA1 could antagonize also other 
effects of BCR-ABL expression, if they are mediated by BRCA1 downregulation, indeed.  
 
0     1     2.5    4     0     1     2.5    4  [h] IM 0,5 μM 
32D                        C4
PARP
BRCA1
A
PARP
- +     - +     - + MG132 10 μM
32D          C2            C4
BRCA1
B
C
PARP
BRCA1
32D      C2      C4
BCR-ABL
actin
BRCA1
0       4      6      4       6   [h]
0,5 μM          5 μM   IM 
C4 cells
 
Fig. 1. The influence of BCR-ABL expression on the level of the BRCA1 Protein. 
A. Expression of BCR-ABL leads to downregulation of the BRCA1 protein. The level of 
BRCA1 was determined by Western Blot in mouse progenitor 32D cells, control or stably 
expressing BCR-ABL at low (C2 cells) or high (C4 cells) level.  
B. Imatinib treatment leads to upregulation of the BRCA1 protein level in cells expressing 
BCR-ABL. 32D and C4 cells were treated with 0.5 μM imatinib for 1, 2.5 or 4 hours (upper 
panel) or with 0.5 or 5 μM imatinib for 4 and 6 hours (lower panel) followed by estimation 
of the BRCA1 protein level.  
C. BRCA1 downregulation caused by BCR-ABL is not a result of increased proteasomal 
degradation. 32D, C2 and C4 cells were treated with 10 μM proteasome inhibitor MG132 for 
6 hours, followed by determination of the BRCA1 protein level by Western Blot. 
Altogether, there are strong evidences indicating that the decrease of the BRCA1 protein and 
the BRCA1-dependent signaling is caused by BCR-ABL expression and is also specific for 
chronic myeloid leukemia, in addition to other types of tumors. There is a number of 
intracellular processes crucial for cell physiology controlled by BRCA1, including DNA 
damage response as well as activation of the cell cycle checkpoints, chromatin remodelling, 
apoptosis and mitosis. Aberrations in any of them, lead to the accumulation of mutations, 
genomic instability and finally an increased risk of cancerogenesis. Thus, we postulate that 
the decrease of BRCA1 caused by BCR-ABL could have tremendous consequences due to 
defective control of genomic stability. The role of BRCA1 in the regulation of the DNA 
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damage response and cell cycle checkpoint control has been already well explained (Huen et 
al., 2010; Kim & Chen, 2008; Wuet al., 2010; Yang & Xia, 2010; Zhang & Powell, 2005). The 
detailed role of BRCA1 in the regulation of mechanisms participating in the occurence of 
genomic instability as a result of mitosis dysfunctions, referred as a CIN (chromosomal 
instability) will be discussed in the next paragraphs.  
4. The role of BRCA1 in mitosis 
4.1 BRCA1 in the transcriptional regulation 
Currently, there is a lot of evidence suggesting that BRCA1 is involved in the transcriptional 
regulation. This opens a new list of possible interactions with intracellular processes 
(Murray et al., 2007). It has been shown that BRCA1 is a component of the RNA polymerase 
II (pol II) holoenzyme (Scully et al., 1997). Authors developed a purification strategy for the 
mammalian pol II holoenzyme to search for specific transcription factors and they found 
that the wild-type BRCA1 protein was copurified. Moreover, immunopurification of BRCA1 
complexes also contained TFIIF, TFIIE and TFIIH transcription factors, which were 
previously reported to form a complex with the pol II holoenzyme (Maldonado et al., 1996). 
This strongly suggested that one of the BRCA1 functions is to regulate genes expression.  
Unlike many enhancer-specific activators, BRCA1 does not appear to require the specific 
DNA binding domain to stimulate gene transcription, what was shown by investigation of 
the p53-responsive promoter MDM2 (Nadeau et al., 2000). BRCA1 interacts rather with 
multiple transcription factors. Among them we can name ATF1, a member of the cAMP 
response element-binding protein/activating transcription factor (CREB/ATF) family. 
BRCA1 stimulates its transcription from a natural promoter as well as reporter systems 
(Houvras et al., 2000). Moreover, BRCA1 significantly enhanced the transcription of NF-
kappaB target genes due to the binding to p65/RelA, one of the two subunits of the 
transcription factor NF-kappaB (Benezra et al., 2003). Authors suggested that BRCA1 acts as 
a coactivator and proposed a model in which BRCA1 interacts physically with p65/RelA, 
CBP as well as with RNA polymerase II and enhances transcriptional activation of the NF-
kappaB target genes. Additionally, MacLachlan reported that p53 can be stabilized by 
BRCA1 in response to DNA damage and by this selectively transactivated towards genes 
involved in the growth arrest and DNA repair (MacLachlan et al., 2002). The role of BRCA1 
in the regulation of p53-dependent gene expression has been also shown by other groups 
(Ouchi et al., 1998; Zhang et al., 1998).  
BRCA1 is also able to interact with components of the histone deacetylase complex, 
particularly with HDAC1 and HDAC2 (Yarden & Brody, 1999). It was shown to interact in 
vitro and in vivo with the Rb protein as well as with the RB-binding proteins, RBAp46 and 
RBAp48, which are components of the histone deacetylase complexes and are involved in 
chromatin remodelling. Involvement of BRCA1 in chromatin remodelling suggests its 
important role in the regulation of transcription, replication, recombination and others. 
BRCA1-mediated activation of specific genes may result from sequestration of histone 
deacetylases from DNA promoters. It was also reported that BRCA1 interacts with the 
hGCN5/TRAP histone acetyltransferase complex (Oishi et al., 2006), which co-activates the 
transactivation function of BRCA1. 
More recently, BRCA1 has also been shown to play a role in the transcriptional repression 
by ubiquitin-dependent mechanism (Horwitz et al., 2007). It leads to ubiquitination of the 
transcriptional preinitiation complex, thus preventing the stable association of TFIIE and 
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TFIIH transcription factors and blocking the initiation of mRNA synthesis. Amphiregulin 
(AREG) and early growth response-1 (EGR-1) are examples of genes repressed by BRCA1 in 
breast cancers. This phenomen could be broader and may contribute to the BRCA1-
mediated tumor suppression. 
4.2 BRCA1 in the regulation of the mitotic checkpoint  
The role of BRCA1 in the regulation of the mitotic checkpoint has been indicated. BRCA1 
was identified as a mitotic target of the Chk2 kinase in the absence of DNA damage (Stolz et 
al., 2010). Accordingly, loss of BRCA1 or its Chk2-mediated phosphorylation led to defects 
in the spindle formation and chromosomal instability (CIN) due to generation of lagging 
chromosomes and chromosome missegregation. It was shown that MCF-7 cells transfected 
with BRCA1 siRNA display a reduced mitotic index followed by premature cyclin B1 
degradation upon paclitaxel treatment. This suggested that BRCA1 depletion results in the 
inactivation of the spindle checkpoint (Chabalier et al., 2006). They presented that BRCA1 
up-regulates the expression of the protein kinase BubR1, an essential component of the 
functional spindle checkpoint. This indicated that BRCA1 directly influences the expression 
of the mitotic checkpoint components. It was also shown that BRCA1, due to an interaction 
with the transcription factor OCT-1, mediates the transactivation of Mad2 (mitotic arrest 
deficient protein 2) (Wang et al., 2004). The studies of BRCA1 knock-down in human 
prostate and breast cancer cell lines, by using the microarray technique, showed that BRCA1 
depletion caused downregulation of many genes involved in mitosis progression (Bae et al., 
2005). Specifically, mitotic checkpoint components (Bub1, STK6), proteins involved in the 
chromosome segregation and centrosome function as well as cytokinesis (including PLK) 
and finally proteins regulating mitosis entry and progression, such as cyclin B1, Cdc2 and 
Cdc20 were downregulated. 
The influence of BRCA1 on the expression of components of the mitotic checkpoint was also 
confirmed in our studies (Wolanin et al., 2010). We showed that the downregulation of 
BRCA1, caused either by BCR-ABL expression or by gene silencing using siRNA, resulted in 
the downregulation of Mad2 as well as BubR1 and Bub3 gene expression, which all belong 
to the mitotic checkpoint complex and undergo common regulation. Decreased levels of 
these proteins finally led to dysfunctions of the mitotic checkpoint and increased occurence 
of aberrant mitoses and chromosomal instability. Moreover, we observed the increased rate 
of supernumerary centrosomes as well as aberrant divisions in cells expressing BCR-ABL. 
We propose that decrease of the BRCA1 protein caused by BCR-ABL could be an important 
factor participating in the development of genomic instability due to the generation of 
chromosomally unstable cells. We added the regulation of mitotic checkpoint to the 
repertoir of BRCA1-mediated mechanisms participating in the development of aneuploidy 
in CML cells.  
Due to its function in the regulation of mitotic checkpoint competence, BRCA1 has been 
shown to correlate with the sensitivity to spindle poisons (Byrski et al., 2008; Quinn et al., 
2007). As mentioned before, cells ability to activate the mitotic checkpoint is necessary for 
the sensitivity to spindle poisons. BRCA1 downregulation resulted in resistance to 
microtubule damage due to the inability to efficiently activate the mitotic checkpoint, block 
cells in mitosis and induce apoptosis. In our studies, cells expressing BCR-ABL with a 
significantly decreased BRCA1 level were resistant to cell death activated by nocodazole or 
paclitaxel (Wolanin et al., 2010). This was reversed by imatinib treatment, resulting in 
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BRCA1 upregulation. In ovarian cancer it was suggested that BRCA1 can act as a predictive 
marker of response to chemotherapy (Quinn et al., 2009) and dysfunctional BRCA1 resulted 
in resistance to taxanes and other chemotherapeutics. On the other hand, reconstitution of 
BRCA1 into ovarian cancer cells, carrying BRCA1 mutation, reversed the resistance and 
sensitized cells to paclitaxel (Zhou et al., 2003). BRCA1 was also proposed as a predicive 
marker of drug sensitivity in breast cancer treatment (Mullan et al., 2006). As resistance to 
spindle poisons has been reported for CML cells, this supports the previously proposed 
idea, that the overexpression of BRCA1 diminishes some effects of BCR-ABL expression. In 
our opinion, BRCA1 level could serve as a prognostic marker of sensitivity to different 
therapies also those used in leukemias. 
4.3 BRCA1 in the regulation of centrosome number and function 
The first observation that BRCA1 localizes to centrosomes has been made by Hsu et al (Hsu 
& White, 1998), who showed that BRCA1 is associated with centrosomes during mitosis in a 
cell cycle-dependent manner. Moreover, they found that BRCA1 forms a complex with 
gamma-tubulin, which is preferentially associated with the hypophosphorylated form of 
BRCA1. Gamma-tubulin is a crucial component of centrosomes and is responsible for 
nucleation of microtubules. Therefore, this confirmed the idea that BRCA1 could play a role 
in the regulation of centrosome amplification and function and led to the later findings that 
a BF3 domain of BRCA1 (BRCA1 fragment no. 3, amino acids 504-803) is responsible for the 
gamma-tubulin binding (Hsu et al., 2001). Overexpression of the BF3 domain in COS-7 cells 
resulted in the accumulation of mitotic cells with supernumerrary centrosomes and 
abnormal spindles, what is known to lead to aneuploidization.  
The role of BRCA1 in the regulation of centrosome number has been indicated by 
experiments using the mutated forms of BRCA1. Centrosomal amplification was shown in 
mouse embryonic fibroblasts carrying a targeted deletion of exon 11 of BRCA1 (Xu et al., 
1999) and in a BRCA1-mutant breast cancer cell line HCC1937 (Schlegel et al., 2003). What is 
important, Waever et al showed that mouse embryonic fibroblasts carrying different BRCA1 
defects show supernumerary centrosomes and other features similar to human breast cancer 
cells, indicating that the mechanisms are conserved between mice and humans (Weaver et 
al., 2002).  
Moreover, immunohistochemical analysis of 50 samples from breast cancer patients showed 
that numerical centrosome aberrations were signicantly associated with the negative BRCA1 
expression as well as with the BRCA1 germline mutation, whereas there was no significant 
correlation with the centrosome aberrations in size (Shimomura et al., 2009). This suggests 
that BRCA1 plays a role rather in the regulation of centrosome duplication and defects in its 
expression or function result in numerical aberrations. Very recently, direct studies of 14 
different missense mutations in the RING domain of BRCA1 and their influence on the 
control of centrosome number were performed (Kais et al., 2011). Authors showed that only 
2 out of the 14 BRCA1 variant proteins were neutral in the centrosome duplication assay. 
The others were either very effective and resulted in mutated BRCA1 proteins that caused 
centrosome amplification (C24R, C27A, C39Y, H41F, C44F, C47G, M18T and I42V) or had an 
intermediate, however still significant effect on centrosome duplication (I21V, I31M, L52F 
and D67Y). 
Interestingly, we also observed a correlation between the loss of BRCA1 expression and 
increased percentage of cells with supernumerary centrosomes in murine lymphoid cells 
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expressing BCR-ABL oncogene (Wolanin et al., 2010). This was in contrast with the hypothesis 
that BRCA1 defects lead to centrosome amplification in breast cells but not in other types of 
cells (Starita et al., 2004). This idea has been based on the data obtained using the transient 
expression of the BRCA1-inhibiting BIF peptide in nine different cell lines, where four non-
breast cell lines - prostate (PC3), cervix (HeLa), colon (DLD-1) and osteosarcoma (U2OS), did 
not accumulate extra centrosomes. However, lymphoid cells were not included in these 
studies. To date, there were other indications, apart from ours, that the loss or mutation of 
BRCA1 could affect the centrosome number also in other types of cells. Recently, it was shown 
that BCR-ABL intereferes with the Fanconi Anemia (FA)/BRCA pathway and the ectopic 
expression of BRCA1 in CD34+ progenitor cells reversed the appearance of aberrant 
centrosomes, thus confirming our previous observations (Valeri et al., 2010). 
The direct mechanism of BRCA1-mediated control of centrosome number is still not fully 
clear, although the BRCA1-dependent ubiquitination of gamma-tubulin is proposed to be 
involved in the regulation of centrosome function (Staritaet al., 2004). Gamma-tubulin is an 
important protein involved in the initiation of microtubule nucleation by centrosomes. 
Gamma-tubulin’s lysines 48 and 344 have been indicated as crucial in the regulation of 
centrosome duplication and microtubule nucleation function, respectively (Sankaran et al., 
2005). Cells with mutated lysines on gamma-tubulin, unable to be ubiquitinated, were 
characterized by centrosome amplification. On the other hand, the same phenotype was 
observed after inhibition of the enzymatic activity of BRCA1 by transfection of the BRCA1 
(I26A) ligase-defective mutant (Sankaran et al., 2006). Additionally, in vitro experiments 
using Xenopus extracts, purified centrosomes and BRCA1 together with ubiquitination 
factors confirmed that BRCA1 is involved in the microtubule nucleation. It seems that 
BRCA1 controls the centrosome number by preventing reduplication due to ubiquitination 
of lysines of gamma-tubulin, which needs to be phosphorylated to prevent reduplication 
(Ko et al., 2006). Loss of BRCA1 did not affect centrosome duplication in the early S phase 
but rather caused a second round of duplication just prior to mitosis. The model has been 
proposed, in which BRCA1 marks centrosomes as already duplicated via the BRCA1-
mediated ubiqutination of gamma-tubulin (Wong & Stearns, 2003). This issue is still not 
fully clarified, however there is no doubt about the significant role of the BRCA1-mediated 
ubiquitination of gamma-tubulin in this process (Kais & Parvin, 2008). Altogether, this led to 
the conclusion that the E3 ubiquitin ligase activity of BRCA1 is crucial for the effects on the 
biology of centrosomes, and controls centrosome duplication as well as microtubules 
nucleation.  
Recently, it was demonstrated that BRCA1 interacts with centrosomal protein Nlp (ninein-
like protein) (Jin et al., 2009), which is a fast turnover protein and plays a role in the 
centrosome maturation and spindle formation (Casenghi et al., 2005). Authors found that 
Nlp is a BRCA1-associated protein and colocalizes with BRCA1 in different types of cancer 
cells, including HeLa and U2OS cells. Moreover, Nlp expression and stability depends on 
normal cellular BRCA1 function. A variety of different types of cells expressing the mutated 
BRCA1 or silenced for BRCA1 exhibited disrupted Nlp colocalization to centrosomes as well 
as enhanced Nlp degradation. This data was consistent with our observations concerning 
the role of BRCA1 in different types of cancers. The lack of Nlp protein led to centrosome 
amplification, aberrant chromosome segregation, cytokinesis failure and appearance of 
miltinuclei, thus resembling the phenotype upon BRCA1 disruption. Recent studies showed 
that Nlp is recruited by the Aurora B protein and localizes at the midbody during 
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cytokinesis, thus its depletion or increased degradation triggers aborted division and 
subsequently leads to multinucleated phenotypes (Yan et al., 2010). 
Altogether, this data strongly supported the idea that BRCA1 is one of the key elements 
controlling mitosis and the loss of BRCA1 could result in very severe dysfunctions of cell 
division. We propose that this can significantly participate in the generation of aneuploidy, 
CML progression and blastic transformation. A proposed model showing the influence of 
BCR-ABL-mediated downregulation of BRCA1 on the occurrence of genomic instability and 
aneuploidy in CML cells is presented in Figure 2. 
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Fig. 2. Proposed scheme of the mechanisms influenced by BCR-ABL-mediated BRCA1 
downregulation; role in the genomic instability and generation of aneuploid cells. 
5. Therapeutic targeting of mitosis in CML cells 
The effects of the improper control of mitosis in the development and progression of 
leukemias, including chronic myeloid leukemia has been already described above. The 
importance of these processes and their potential as targets for therapy is already obvious. 
In general, looking for new treatment options or combined therapies is still necessary to 
overcome the insensitivity or resistance to tyrosine kinase inhibitors, often developed in 
CML patients. In our opinion, targeting the chromosomal passenger complex and mitotic 
kinases is a very promising trend in the development of novel anti-leukemia therapeutic 
strategies. We will discuss the current data and implications for the future.  
5.1 Chromosomal passenger complex and Aurora kinases  
The chromosomal passenger complex (CPC) is a group of proteins, which are involved in 
the regulation of nearly all stages of mitosis (Vader et al., 2006; Vagnarelli & Earnshaw, 2004; 
Yanet al., 2010). In most organisms, the chromosomal passenger complex is formed by four 
main proteins: Aurora B kinase, INCENP, Survivin and Borealin/Dasra-B (Ruchaud et al., 
2007). Other proteins, like telophase disk 60 kDa (TD-60) have been shown to interact with 
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the CPC proteins and have a typical localization, however they are not members of the core 
complex. The complex undergoes a characteristic scenario of translocations during mitosis – 
they localize at the inner centromeres in prometaphase and metaphase then, at anaphase 
onset, they leave the chromosomes and transfer to the kinetochores at the central spindle to 
finally move to the midbody at cytokinesis. It plays a crucial role in the regulation of 
chromatin condensation, kinetochore function, mitotic checkpoint competence as well as 
cytokinesis (Terada, 2001; Vaderet al., 2006). Very recently it was presented that the 
chromosomal passenger complex is essential for correcting the non-bipolar chromosome 
attachments and for cytokinesis (Becker et al., 2010). To do this, Aurora B and INCENP have 
to be localized to centromeres. This is a very important finding as it indicates the supportive 
role of the CPC complex in case of mitotic checkpoint failure. Moreover, the translocation of 
Aurora B and other CPC proteins from centromeres to the spindle midzone in anaphase is 
necessary to prevent mitotic checkpoint engagement at anaphase (Vazquez-Novelle & 
Petronczki, 2010). 
Members of the CPC complex have been proposed as very potent therapeutic targets. 
Treatment of imatinib-resistant CML cells carrying the T315I mutation with small molecule 
inhibitor, PHA-739358, which selectively targets BCR-ABL and Aurora kinases led to strong 
antiproliferative and apoptotic effects (Gontarewicz et al., 2008). Moreover, this has also 
been observed in CD34+ cells derived from untreated CML patients and from imatinib-
resistant patients in the chronic phase or blast crisis, including those harbouring the T315I 
mutation. Similar effects were obtained by combined treatment of imatinib resistant CML 
cells with vorinostat together with Aurora kinase inhibitor MK-0457 (Dai et al., 2008). 
Effectivity of this combined treatment has been shown against primary CD34+ CML cells, 
murine Ba/F3 cells with various BCR-ABL mutations (T315I, E255K, and M351T), as well as 
in imatinib-resistant K562 cells with BCR-ABL-independent, Lyn-dependent resistance. The 
same combination of therapy was presented also in other studies by Fiskus et al (Fiskus et 
al., 2008). Authors studied different CML cell lines, murine cells expressing BCR-ABL as 
well as primary CML and AML cells and came to the same conclusions. Novel inhibitors of 
Aurora kinases are still investigated in the anti-leukemia therapy of imatinib-resistant cells 
(Fei et al., 2010; Kelly et al., 2010). Usually they are proposed to be used together with 
tyrosine kinase inhibitors, such as imatinib or dasatinib.  
Survivin has been also proposed as a universal target for anticancer therapy (Andersen et 
al., 2007). Several trials are currently undergoing, using different methodologies, from small 
molecule antagonists to immunotherapy (Kanwar et al., 2010). However, the development 
of survivin inhibitors is not as advanced as other therapeutic small inhibitors. It is important 
to point that anti-survivin therapy should be probably combined with other treatments, as it 
is known that survivin depletion uncovers the function of the mitotic as well as post-mitotic 
p53-p21-dependent checkpoints, which protect from polyploidization upon mitosis 
disturbances (Beltrami et al., 2004). In case of cancers with the defective p53 function, 
survivin silencing led to reduced mitotic arrest and enhanced polyploidy, what is a very 
unwanted and dangerous side-effect. Also in our studies, specific depletion of survivin by 
siRNA approach in CML cells with checkpoints defects, resulted in strong polyploidization 
and chromosomal instability (Wolanin et al., 2006). However, when we used a natural 
compound – curcumin, which has been shown as a broadly acting, very potent anticancer 
agent, we found that it affects the CPC proteins and induces mitotic catastrophe, however 
without polyploidization. Curcumin decreased the level of survivin and caused unproper 
localization of Aurora B, leading to perturbances in mitosis and defective cytokinesis.  
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Thus, the status of the mitotic checkpoint competence as well as p53 should be taken into 
consideration when anti-survivin therapy is proposed. Another natural compound, 16-
hydroxycleroda-3,13-dien-15,16-olide (PL3), one of the clerodane diterpenoid compounds 
isolated from Polyalthia longifolia, induced degradation of Aurora B, mitotic checkpoint 
dysfunctions and finally led to cell death of CML cells, including the T315I-mutated BCR-
ABL+ BA/F3 cells (Lin et al., 2011). Additionally, it reversed the sensitivity to imatinib of 
T315I-mutated CML cells in comparizon to treatment only with imatinib.  
Recently, Aurora inhibitors were indicated as promising agents for acute myeloid and 
chronic myeloid leukemias (Moore et al., 2010). The most promising data was obtained for 
FLT3-mutated AML and imatinib-resistant Ph+ CML, particularly with the T315I mutation. 
Clinical trials investigating these agents have been already initiated (Cheung et al., 2011). 
5.2 Polo-like kinases 
Polo-like kinases are of strong interest according to potential anticancer therapy, as similarly 
to Aurora kinases, they can be targeted with selective small molecule inhibitors (Warner et 
al., 2008). Additionally, many natural compounds with the ability to prevent cancerogenesis, 
such as wortmanin, quercetin, thymoquinone, genistein, indirubin and others, have been 
shown to modulate PLK1 level or activity. It is proposed that naturally occurring PLK1 
inhibitors with low or no toxicity should be considered as interesting agents in prevention 
as well as treatment of cancer (Schmit et al., 2010).  
As described before, PLK1 has been upregulated in different cancers, including leukemias. 
Its inhibition or silencing resulted in cell cycle arrest, decrease of cell viability and induction 
of apoptosis in various cancer cells. Inhibition of PLK1 by different small molecule 
compounds in acute myeloid leukemia (AML) cells led to mitotic accumulation and 
apoptosis (Didier et al., 2008). Comprehensive studies of PLK1 silencing and inhibition 
using the novel selective inhibitor GW843682X in a broad range of different leukemia cell 
lines and primary cells led to the conclusion that PLK1targeting can be a promising strategy 
(Ikezoeet al., 2009). This observation was confirmed by other studies of leukemia primary 
cells (Renneret al., 2009). The potential of PLK1 inhibition to improve the chemotherapy or 
irradiation of resistant leukemia cells has been also investigated in primary patient cells as 
well as in vivo, in mouse Xenograft models of B-lineage ALL studies, with the same 
conclusions (Uckun et al., 2010). Currently, several PLK1 inhibitors are in different phases of 
clinical development for anticancer therapy (Chopra et al., 2010; Schoffski, 2009). Data from 
one of the first clinical trials indicated that the PLK1 inhibitor BI 2536 was well tolerated and 
showed antitumor activity in patients with advanced solid tumors and refractory or 
relapsed AML (Wasch et al., 2010). According to CML, this scheme of therapy was not very 
intensively studied till now, however it also seems to be very potent and prospective. PLK1 
inhibitor BI 2536 in a low, nanomolar concentration was able to induce growth inhibition 
and mitotic arrest followed by apoptosis in CML cells, including cell lines and primary cells 
from patients (Gleixneret al., 2010). Importantly, this agent was very effective not only 
against imatinib-sensitive CML cells, but also imatinib-resistant cells carrying the T315I 
mutation. Treatment with BI2536 together with imatinib or nilotinib showed synergistic 
effect, indicating possibility of a combined therapeutic application.  
6. Final conclusions 
Taken together, it is already clear that BRCA1 due to its multifunctional nature, is one of the 
key molecules controlling mitosis on the different levels of organization. There is no doubt 
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that the decrease of BRCA1 caused by BCR-ABL in CML cells could be a critical factor 
determining the generation of supernumerary centrosomes, aberrant mitotic spindles, 
mitosis and cytokinesis failures, finally leading to aneuploidization. All data presented in 
this review convincingly show that activity of the BCR-ABL kinase is directly responsible for 
the promotion of chromosomally unstable phenotype. As chromosomal instability seems to 
play a crucial role in the disease progression, mitosis is a prospective target for treatment in 
CML. This opens new possibilities for therapeutical intervention based on the targeting 
processes involved in the control of mitosis. It can be an alternative strategy for alone or 
combined treatment of leukemia cells, which developed resistance to imatinib or second-
generation tyrosine kinase inhibitors, such as dasatinib or nilotinib.  
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